Oral cephalosporins: current perspectives.
J. García-Rodríguez, J. L. Muñoz Bellido, J. E. García Sánchez
Jul 1, 1995
Citations
22
Citations
Journal
International journal of antimicrobial agents
Full text
Semantic Scholar
Key Takeaway Key Takeaway: Oral cephalosporins show promising potential as an outpatient alternative for treating mild to moderate infections in ENT, UTIs, STDs, lower respiratory tract, and skin and soft tissue, with improved pharmacokinetics and resistance to extended-spectrum beta-lactamases.
Abstract
Oral cephalosporins had been, for years, a small group of compounds belonging to the first or second-generation cephalosporins, with a limited antimicrobial spectrum. New oral first-generation cephalosporins include cefprozil and loracarbef, similar to cefadroxil and cefaclor, respectively, with activity similar to cefaclor but with pharmacokinetic improvements. Second-generation oral cephalosporins are esters of already available cephalosporins, and third-generation oral cephalosporins include a number of drugs whose activity is similar to available parenteral drugs, showing pharmacokinetic advantages and, some of them, better resistance to hydrolysis mediated by extended wide-spectrum beta-lactamases. They may be a good alternative against mild to moderate ENT infections, UTIs, STDs, lower respiratory tract and skin and soft tissue infections, mainly in the outpatient setting.